Events

Connected medical devices are becoming essential in healthcare, but is the incremental innovation we’ve seen in the past enough or must medtech now embrace true digital disruption? The short answer is, yes. Medical device companies can lead disruption now or risk being forced in a new direction by others, such as tech giants entering this market.

In this webinar, Bill Betten, Director of Medtech Solutions at S3 Connected Health, and Michael Hill, PhD, recently retired from Medtronic as VP Corporate Science & Technology and Innovation, will share their industry experience and discuss how medical device companies can lead disruption by:

• Enabling more remote, holistic, personalized care from hospital to home through appropriate and timely data collection, analysis, and insights
• Changing company mindsets to become more than device providers, and adapting internal structures to fuel transformation
• Championing value-based care for reduced cost, ease of care delivery, and improved outcomes

In this webinar, our own Jim O'Donoghue will be joined by Andrew Wright of H1 Consulting and Hans-Peter Frank of T-S-P Health GmbH to share insights and provide actionable advice on how to develop and launch SaMD digital health solutions that address pharma’s challenges, including:

• Why SaMD is important for digital health, the capabilities required, and the best approach for pharma when developing solutions
• Assessing the medical device classification of solutions and how this impacts your business strategy, development plan, and regulatory roadmap
• Choosing the best region for launch and how it will determine the level of evidence and validation required, and what reimbursement models are available

We are excited to announce that Matt Norton, VP of Marketing & Commercial Development will be presenting at this year's DTx Europe Conference, which this year will focus on Defining the Success of Digital Therapeutics.

Co-creating, partnering, and licensing DTx: The trade-offs for pharma on responsibilities, risk, and retaining commercial control:

• What are the trade-offs and potential downsides
• What is the right mix to build success: responsibilities, risk, and commercial control
• Our experience and learnings from the co-creation of DTx

Contact us to meet during the conference and learn more about how we partner with pharma to create digital health solutions that improve the lives of people with acute and chronic conditions.